RETATRUTIDE

Key Functions & Benefits

• Mechanism (“Triple G”): Unlike Wegovy (GLP-1) or Mounjaro (GIP/GLP-1), retatrutide targets three receptors—Glucagon-like peptide-1 (GLP-1), Gastric inhibitory polypeptide (GIP), and Glucagon—to suppress appetite, increase energy expenditure, and regulate blood sugar.
• Efficancy: Phase 2 studies showed up to 24.2% body weight loss over 48 weeks at the highest dose, making it a potential “game changer” in obesity treatment. It has also demonstrated significant improvements in blood pressure, fat mass reduction, and blood sugar management.
• Availability: It is not yet approved or commercially available. It is in Phase 3 clinical trials, with anticipated FDA approval potential for late 2026 or early 2027.
• Side Effects: Similar to other GLP-1 agonists, side effects include nausea, diarrhea, vomiting, and constipation.